Research
Clinical trials
Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.
Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.

Recruiting and upcoming studies
The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.
Showing 1–12 of 208 trials
RecruitingAL (light chain)
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma (opens on ClinicalTrials.gov)
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Janssen Research & Development, LLC
Recruiting in: AustraliaIsraelNetherlandsSpain+1
NCT06768489Updated 25 September 2026
RecruitingATTR (transthyretin)
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis (opens on ClinicalTrials.gov)
Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this…
- Study
- Interventional (treatment)
- Phase
- Phase 4
- Sponsor
- Bayer
Recruiting in: AustriaBelgiumGermanyItaly+1
NCT07298044Updated 25 September 2026
RecruitingAL (light chain)
BE.Amycon Biobank & Data Registry UZ Leuven (opens on ClinicalTrials.gov)
The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank "BE.Amycon biobank" for…
- Study
- Observational (registry, imaging)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Recruiting in: Belgium
NCT07172243Updated 25 September 2026
Not yet recruitingATTR (transthyretin)
Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor (opens on ClinicalTrials.gov)
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This…
- Study
- Observational (registry, imaging)
- Sponsor
- Bayer
Recruiting in: AustriaGermanyItaly
NCT07557147Updated 24 September 2026
Not yet recruitingATTR (transthyretin)
[18F]FIDT-10b PET Imaging in Cardiac Amyloidosis (opens on ClinicalTrials.gov)
This is a first in human study that will assess the safety, pharmacokinetics, biodistribution and diagnostic performance of [18F]FIDT-10b (fluorine-18 labeled FIDT-10b), a positron…
- Study
- Interventional (treatment)
- Phase
- Phase 1
- Sponsor
- Peking Union Medical College Hospital
Recruiting in: China
NCT07835880Updated 23 September 2026
Not yet recruitingATTR (transthyretin)
Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis (opens on ClinicalTrials.gov)
The goal of this clinical trial is to learn if trimetazidine can improve blood flow in the heart in adults with transthyretin cardiac amyloidosis…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Fábio Fernandes
Recruiting in: Brazil
NCT07836699Updated 23 September 2026
Not yet recruitingNot specified
Individualized Exercise Training in Cardiac Amyloidosis (opens on ClinicalTrials.gov)
Numerous clinical trials have demonstrated that transthyretin (TTR)-directed medical therapies can reduce the rate of functional decline in patients with transthyretin cardiac amyloidosis (ATTR-CM).…
- Study
- Interventional (treatment)
- Sponsor
- Oregon Health and Science University
No study locations listed yet
NCT07835867Updated 23 September 2026
RecruitingATTR (transthyretin)
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis (opens on ClinicalTrials.gov)
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease…
- Study
- Observational (registry, imaging)
- Sponsor
- AstraZeneca
Recruiting in: CanadaChinaGermanySpain+2
NCT06465810Updated 23 September 2026
RecruitingNot specified
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) (opens on ClinicalTrials.gov)
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Eli Lilly and Company
Recruiting in: JapanSouth KoreaTaiwanUnited States
NCT07589595Updated 22 September 2026
RecruitingATTR (transthyretin)
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis (opens on ClinicalTrials.gov)
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with…
- Study
- Interventional (treatment)
- Phase
- Phase 3
- Sponsor
- Novo Nordisk A/S
Recruiting in: ArgentinaAustraliaBelgiumBrazil+16
NCT07207811Updated 22 September 2026
RecruitingNot specified
Beta-amyloid PET/CT to Measure Potential Therapeutic Response in AL-CA (opens on ClinicalTrials.gov)
This was a single center, prospective cohort study that is evaluating the ability of beta-amyloid dynamic PET/CT to detect potential therapeutic changes in subjects…
- Study
- Interventional (treatment)
- Phase
- Phase 2
- Sponsor
- Peking Union Medical College Hospital
Recruiting in: China
NCT07829705Updated 21 September 2026
RecruitingNot specified
Prevalence of Cardiac Thrombi in Cardiac Amyloidosis (opens on ClinicalTrials.gov)
Cardiac amyloidosis (CA) is an infiltrative disease characterized by deposits of amyloid proteins of genetic or acquired origin (often in elderly patients), leading to…
- Study
- Interventional (treatment)
- Sponsor
- Centre Hospitalier Universitaire Dijon
Recruiting in: France
NCT07648303Updated 17 September 2026
This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 25 September 2026. clinicaltrials.gov
Not sure where to start?
Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.